The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com

PARTNER NEWS:

Wed, Mar 5, 9:58 AM, Zacks
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.

Thu, Dec 19, 8:39 AM, Zacks
Hyperion Therapeutics (HPTX) Jumps: Stock Adds 5.2% - Tale of the Tape
Hyperion Therapeutics, Inc. was a big mover last session, as its shares rose over 5% on the day.

Hyperion Therapeutics, Inc. (HPTX)

Hyperion Therapeutics is a development stage biopharmaceutical company focused on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. Co.'s product candidate, Ravicti™ (glycerol phenylbutyrate), is designed to lower ammonia in the blood. Co. has developed Ravicti to treat most urea cycle disorders, and are developing Ravicti to treat hepatic encephalopathy, two different diseases in which blood ammonia is elevated.

Company Name:  Hyperion Therapeutics, Inc.
Website:  www.hyperiontx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding HPTX:  13
Total Market Value Held by ETFs:  $6.23M
Total Market Capitalization:  $504.00M
% of Market Cap. Held by ETFs:  1.24%
April 19, 2014    11:09 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade HPTX Now:



Strong Buy (3.75 out of 4)
84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Hyperion Therapeutics, Inc. (HPTX) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.